Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 4-9 , March 2009

Hepatitis C intervention research – Where are we now and where should we be heading?

  • Tahany Awad

      Affiliations

    • Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 35 45 71 75; fax: +45 35 45 71 01.
    • ,
  • Kristian Thorlund

      Affiliations

    • Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    • ,
  • Mahasen Mabrouk

      Affiliations

    • Department of Endemic Medicine, Cairo University, Cairo, Egypt
    • ,
  • Christian Gluud

      Affiliations

    • Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark

References 

  1. World Health Organization. Hepatitis C; 2000. <http://www.who.int/mediacentre/factsheets/fs164/en/> [homepage on the Internet].
  2. World Health Organization. Surveillance and control; 2008. <http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html> [homepage on the Internet].
  3. Habib M, Mohamed MK, Abdel Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology. 2001;33(1):248–253
  4. Esmat G, El Razikyn M. Management of chronic hepatitis C virus genotype 4 infection. Arab J Gastroenterol. 2007;8(2):38–43
  5. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–891
  6. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39(4):1147–1171
  7. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2005;(4):CD005527
  8. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev. 2005;(3):CD005445
  9. Simin M, Brok J, Stimac D, et al. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1153–1162
  10. Awad T, Thorlund K, Hauser G, et al. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C. In: The Cochrane Hepato-Biliary Group bi-annual meeting at the 2008 AASLD meeting, San Francisco; 2008.
  11. Al Faleh FZ, Huraib S, Sbeih F, et al. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia. J Viral Hepat. 1995;2(6):293–296
  12. Shobokshi OA, Serebour FE, Skakni L, et al. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol. 1999;58(1):44–48
  13. Koshy A, Madda JP, Marcellin P, et al. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002;35(1):82–85
  14. Fretz C, Jeannel D, Stuyver L, et al. HCV infection in a rural population of the central african republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol. 1995;47(4):435–437
  15. Oni AO, Harrison TJ. Genotypes of hepatitis C virus in Nigeria. J Med Virol. 1996;49(3):178–186
  16. Sanchez Quijano A, Abad MA, Torronteras R, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol. 1997;27(1):25–29
  17. Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis. 2002;42(3):169–173
  18. Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol. 1998;29(1):169
  19. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005;436(7053):953–960
  20. Pocock SJ. Clinical trials: a practical approach. John Wiley and Sons; 1996;
  21. Egger M, Smith GD, O’Rourke K. Rationale, potentials and promise of systematic reviews. In:  Egger M,  Smith GD,  Altman D editor. Systematic reviews in health care. Meta-analysis in context. London: BMJ Books; 2001;
  22. Greenland S, Morgenstern H. Confounding in health research. Annu Rev Public Health. 2001;22:189–212
  23. Tatsioni A, Zarin DA, Aronson N, et al. Challenges in systematic reviews of diagnostic technologies. Ann Intern Med. 2005;142(12 Pt. 2):1048–1055
  24. D’Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31(5):468–475
  25. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores – where are we and where should we go?. J Hepatol. 2004;41(2):344–350
  26. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–788
  27. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med. 2005;142(12 Pt. 2):1090–1099
  28. Vist GE, Bryant D, Somerville L, et al. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev. 2004;(4):MR000009
  29. Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatol. 2006;44(3):607–615
  30. Becker U, Burroughs AK, Cales P, et al. Trials in portal hypertension: valid meta-analyses and valid randomized clinical trials. In:  De Franchis R editors. Portal hypertension II: proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science Ltd.; 1996;p. 180–209
  31. Gluud C, Kjaergard LL. Quality of trials in portal hypertension and other fields of hepatology. In: Third Baveno international consenus workshop. Portal hypertension into the third millennium. Definition methodology and therapeutic strategies in portal hypertension. Oxford: Blackwell Science; 2001;p. 204–218
  32. Kjaergard LL, Frederiksen SL, Gluud C. Validity of randomized clinical trials in gastroenterology from 1964–2000. Gastroenterology. 2002;122(4):1157–1160
  33. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2008.
  34. Gluud C, Nikolova D, Klingenberg SL, et al. Cochrane Hepato-Biliary Group. About the Cochrane Collaboration. Cochrane Review Groups (CRGs). The Cochrane Library; 2008.
  35. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412
  36. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998;352(9128):609–613
  37. Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287(22):2973–2982
  38. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–605
  39. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291(20):2457–2465
  40. Hulley SB, Cummings SR, Browner WS, et al. Designing clinical research: an epidemiologic approach. 3rd ed.. Lippincott Williams and Wilkins; 2006;
  41. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed.. Wiley–Interscience; 2002;
  42. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203–2209
  43. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials?. Stat Med. 1984;3(4):409–422
  44. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med. 2008;5(1):e4
  45. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–2618
  46. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289–293
  47. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–699
  48. Myers RP, Patel K, Pianko S, et al. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat. 2003;10(1):16–22
  49. El Zayadi AR, Attia M, Badran HM, et al. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. Liver Int. 2005;25(4):746–751
  50. El Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005;100(11):2447–2452
  51. Esmat G, Abouzied A, Abdel-Hamid M, et al. Results of a randomized clinical trial of genotype 4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. Hepatology. 2003;38(4 Suppl. 1):314A
  52. Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007;46(4):620–627
  53. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol. 2006;12(35):5692–5698
  54. Birkel A, Caldwell L, Stafford Fox V, et al. Combination interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications. Gastroenterol Nurs. 2000;23(2):55–62
  55. Wartelle Bladou C, Rosenthal E, Ratziu V, et al. Adhesion a la bitherapie pegylee au cours de l’hepatite chronique C. Importance du trio hepatologue, medecin generaliste, infirmiere [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner and nurse]. Gastroenterol Clin Biol. 2008;32(3 Pt. 2):S96–S108
  56. Larrey D, Couzigou P, Denis J. Hepatite chronique C: Gestion des effets indesirables du traitement [Chronic hepatitis C: management of side effects of treatment]. Gastroenterol Clin Biol. 2007;31(8–9 Pt. 3):4S20–8
  57. Vermehren J, Kau A, Gartner BC, et al. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (versant HCV RNA 3.0) for RNA detection and quantification.. J Clin Microbiol. 2008;46(12):3880–3891
  58. Sizmann D, Boeck C, Boelter J, et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol. 2007;38(4):326–333
  59. Sarrazin C, Gartner BC, Sizmann D, et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol. 2006;44(3):729–737
  60. Chevaliez S, Bouvier Alias M, Brillet R, et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007;46(1):22–31
  61. Gluud C, Brok J, Gong Y, et al. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46(4):734–742

PII: S1687-1979(09)00003-3

doi: 10.1016/j.ajg.2009.03.005

Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 4-9 , March 2009

Article Tools